1.04
-0.05(-4.59%)
Currency In USD
| Previous Close | 1.09 |
| Open | 1.08 |
| Day High | 1.1 |
| Day Low | 1.04 |
| 52-Week High | 3.83 |
| 52-Week Low | 0.22 |
| Volume | 458,382 |
| Average Volume | 944,460 |
| Market Cap | 76.53M |
| PE | -2.21 |
| EPS | -0.47 |
| Moving Average 50 Days | 1.4 |
| Moving Average 200 Days | 1.22 |
| Change | -0.05 |
If you invested $1000 in Cognition Therapeutics, Inc. (CGTX) since IPO date, it would be worth $81.44 as of February 21, 2026 at a share price of $1.04. Whereas If you bought $1000 worth of Cognition Therapeutics, Inc. (CGTX) shares 3 years ago, it would be worth $636.09 as of February 21, 2026 at a share price of $1.04.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cognition Therapeutics Extends Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
GlobeNewswire Inc.
Feb 05, 2026 12:30 PM GMT
PURCHASE, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, has extended the duration of the expand
Cognition Therapeutics Completes Type C Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies
GlobeNewswire Inc.
Jan 27, 2026 12:30 PM GMT
PURCHASE, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, conducted a Type C meeting with the U.S. Fo
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies
GlobeNewswire Inc.
Jan 06, 2026 12:30 PM GMT
- Zervimesine exhibited meaningful improvement in behavioral, functional, cognitive, and movement measures compared to placebo -PURCHASE, N.Y., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), today announced that a ma